Table 3 Relapses/progressions in 16 stage 1 patients without MYCNA

From: Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group

Case no.

Age (months)

Primary site

Histopathology

LDH

Ploidy

Site/time to relapse/progression

Therapy

Outcome

 1

0

A

E

Skin, 4 months

None

CR, 81 months

 2

1

A

F

N

B, Skin, L, 3 months

None

CR, 74 months

 3

1

Neck

F

An

Local, 3 months

CT

CR, 122 months

 4

1

A

F

An

Local, 10 months

CT

CR, 87 months

 5

2

A

F

N

L, 2 months

CT

CR, 62 months

 6

2

A

F

N

An

B, Skin, L, 5 months

None

CR, 67 months

 7

5

A

F

N

D

Local, B, 11 months

None

CR, 58 months

 8

7

A

F

N

An

BM, 1 month

CT

CR, 117 months

 9

10

T

F

N

An

Local, 3 months

None

CR, 112 months

10

11

A

F

N

D

Local, 48 months

CT, RT

CR, 92 months

11

26

T

F

An

Local, 23 months

CT, S

CR, 37 months

12

26

A

U

N

An

B, BM, 3 months

CT, S

CR, 127 months

13

52

A

E

D

BM, 11 months

None

CR, 70 months

14

59

A

N

Local, B, 10 months

CT

CR, 89 months

15

71

T

D

Local, BM, 5 months

CT

DOD, 24 months

16

169

A

Local, B, BM, 35 months

CT, RT

TD, 38 months

  1. A=abdomen; An=aneuploid; B=bone; BM=bone marrow; CR=complete remission; CT=chemotherapy; D=diploid; DOD=dead of disease; E=elevated; F=favourable; L=liver; N=normal; RT=radiotherapy; S=surgery; T=thorax; TD=toxic death; U=unfavourable.